Form D · Other Health Care
Genomic Cancer Institute, Inc.
Tampa, FL · CIK 0001663181
Offering snapshot reported Jan 8, 2016 · SEC filing
- Reported sold
- Yet to sell Offering amount: $1.5M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 8, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $40K (estimated)
- Form D file number
- 021-254824
Source: Form D, filed Jan 8, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Francis | Director |
| Steve Gorlin | Director |
| Garry Latimer | Director, Executive |
| Matthew Miller | Director, Executive |
| John Sauickie | Director, Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
403 East Madison Street Suite 400
Tampa, FL, 33602
Tampa, FL, 33602